Nevirapine versus efavirenz based antiretroviral treatment in naïve Indian patients: Comparison of effectiveness in clinical cohort

Journal of Association of Physicians of India

Volumn 54, Issue DEC., 2006, Pages 915-918

  Patel, A K ^a   Pujari, S ^b   Patel, K ^a   Patel, J ^c   Shah, N ^a   Patel, B ^d   Gupte, N ^b  

^a Infectious Diseases Clinic   (India)

^b A Ruby Hall Clinic ^*

^c Adit Diagnostic Center   (India)

^d Shashwat Microbiology   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; OXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INDIA; MALE; PROSPECTIVE STUDY;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MALE; NEVIRAPINE; OXAZINES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33947593830     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338: 853-60.
2. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. Federation National des Centres de Lutte le SIDA. AIDS 1997;11: F101-5.
3. Mocroft A, Vella S, Bevfield TL, et al. Changing pattern of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
5. Moyle GJ, Gazzard BG. A risk-benefit assessment of HIV protease inhibitors. Drug Saf 1999;20:299-321.
6. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:161-78.
7. World Health Organization. Scaling up antiretroviral therapy in resource limited settings- Guidelines for public health approach. WHO, 2002.
8. Moyle GJ. Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection. Curr Opin Infect Dis 2000;13:19-25.
9. Barreiro P, Garcia-Banayas T, Soriano V, et al. Simplification of antiretroviral treatment: how to sustain success, reduce toxicity and ensure adherence avoiding PI use. AIDS Rev 2002;4:233-41.
10. Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of nonnucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral experienced patients. AIDS 2001;15:2385-95.
11. Torre D, Tambini R, Speranza F. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials. HIV Clin Trials 2001;2:113-21.
12. Manfredi R, Calza L, Chiodo F. A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use. J Antimicrob Chemother 2002;49:723-29.
13. Manfredi R, Rizzo E, Calza L, et al. The use of efavirenz as a part of a late rescue antiretroviral treatment. HIV Clin Trials 2001;2:413-20.
14. Bell C, Matthews GV, Nelson MR. Non-nucleoside reverse transcriptase inhibitors: an overview. Int J STD AIDS 2003;14:71-7.
15. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002;18:835-8.
16. Casado JL, Moreno A, Hertogs K, et al. Extent and importance of cross-resistance to efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002;18:771-5.
17. Quiros-Roldan E, Airoldi M, Moretti F, et al. Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. J Clin Lab Annal 2002;16:76-8.
18. Campiani G, Ramunno A, Maga G, et al. Non-nucleoside reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Des 2002;8:615-57.
19. Keiser P, Nassar N, White C, et al. Comparison of nevirapine- and efavirenz containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002;3:296-303.
20. Nun̂ez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish Efavirenz vs. Nevirapine Comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials 2002;3:186-94.
21. Cozzi-Lepri A, Phillips AN, D'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis 2002;185:1062-9.
22. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63.
23. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10.
24. Chiesa E, Bini T, Adorni F, et al. Simplification of protease inhibitor containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Antivir Ther 2003;8:27-35.
25. Asboe D, Mandalia S, Gazzard BG. Sequencing to NRTI plus NNRTI only combinations after virological failure of protease inhibitor-based combination HIV-1 therapy. HIV Clin Trials 2003;4:1-10.
26. Pujari S, Patel A, Naik E, et al. Effectiveness of Generic Fixed-Dose Combinations of Highly Active Antiretroviral Therapy for Treatment of HIV Infection in India. J Acquir Immune Defic Syndr 2004;37:1566-9.
27. Roberto Manfredi, Leonardo Calza, Francesco Chiodo, et al. Efavirenz Versus Nevirapine in Current Clinical Practice: A Prospective, Open-Label Observational Study. J Acquir Immune Defic Syndr 2004;35:492-502.